DDInter513 DDInter1676
Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone]. Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Dexamethasone {u} (Compound) resembles {v} (Compound) Fludrocortisone
Dexamethasone {u} (Compound) resembles {v} (Compound) Triamcinolone
Dexamethasone {u} (Compound) treats {v} (Disease) psoriatic arthritis
Dexamethasone {u} (Compound) binds {v} (Gene) CYP3A7-CYP3A51P
Dexamethasone {u} (Compound) upregulates {v} (Gene) PCYOX1L
Dexamethasone {u} (Compound) palliates {v} (Disease) kidney cancer
Dexamethasone {u} (Compound) is included by {v} (Pharmacologic Class) Corticosteroid Hormone Receptor Agonists
Dexamethasone {u} (Compound) downregulates {v} (Gene) DNAJB6
Dexamethasone {u} (Compound) causes {v} (Side Effect) Vitreous opacities
Dexamethasone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sodium bicarbonate
Dexamethasone (Compound) resembles Fludrocortisone (Compound)
Dexamethasone (Compound) resembles Triamcinolone (Compound)
Dexamethasone (Compound) treats psoriatic arthritis (Disease)
Dexamethasone (Compound) binds CYP3A7-CYP3A51P (Gene)
Dexamethasone (Compound) upregulates PCYOX1L (Gene)
Dexamethasone (Compound) palliates kidney cancer (Disease)
Dexamethasone (Compound) is included by Corticosteroid Hormone Receptor Agonists (Pharmacologic Class)
Dexamethasone (Compound) downregulates DNAJB6 (Gene)
Dexamethasone (Compound) causes Vitreous opacities (Side Effect)
Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Sodium bicarbonate